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The intestinal tract is a recognized reservoir of antibiotic-resistant organisms (ARO), and a potential target for strategies to reduce
ARO colonization. Microbiome therapies such as fecal microbiota transplantation (FMT) have been established as an effective treatment for recurrent Clostridioides difficile infection and may be an effective approach for reducing intestinal ARO colonization. In
this article, we review the current published literature on the role of FMT for eradication of intestinal ARO colonization, review the
potential benefit and limitations of the use of FMT in this setting, and outline a research agenda for the future study of FMT for
intestinal ARO colonization.
Keywords: antibiotic resistance; antibiotic-resistant organism; fecal microbiota transplantation; hospital epidemiology;
microbiome; multidrug-resistant organisms; resistome.
The US Centers for Disease Control and Prevention has estimated
that each year >2 000 000 patients are infected with antibioticresistant organisms (AROs) and 23 000 die of these infections [1].
Infections due to AROs represent an urgent threat to public health
and rates of antibiotic resistance are increasing faster than the development of new antimicrobials [2, 3]. The intestinal tract can
function as a reservoir for AROs, meaning AROs can be present
without causing clinical symptoms [4]. Patients who are colonized
with AROs are at risk of ARO infection and ARO transmission
to other individuals (Figure 1) [5]. Although aggressive infection prevention interventions can help reduce their spread, these
efforts do not control the source of ARO colonization [6, 7].
Multiple studies have used antimicrobials in an attempt to reduce ARO colonization or infection. However, demonstration of
improvement in clinical end points has been inconsistent. The
use of antimicrobials may also have unintended consequences of
selection and expansion of AROs [8–11]. Thus, existing strategies
can perpetuate a vicious cycle of increasing antimicrobial use,
and pressure for expansion of antimicrobial resistance.
The intestinal microbiome of healthy patients is often
characterized as diverse and resistant to ARO colonization. This
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protection from ARO colonization has bolstered enthusiasm for
study of fecal microbiome therapeutics as an antibiotic-sparing
approach to address antimicrobial resistance [5]. In the current
article, we review published data on the role of fecal microbiota
transplantation (FMT) for ARO control, summarize reported
clinical outcomes data for the use of FMT to directly reduce
ARO colonization, and outline a research agenda for advancing
understanding of FMT for this application.
ARO COLONIZATION AS A COMPLEX PHENOMENON

Studies of ARO colonization have used different definitions
of colonization and loss of colonization. This complicates
the interpretation of estimates across settings. The detection
of even a single isolate with a transmissible resistance mechanism is likely to have important public-health implications.
However, the minimum criteria for colonization may lack specificity and in some cases may be overly sensitive. On the other
hand, definitions of loss of colonization have also varied and
may not be sensitive enough. Documentation with 3 consecutive negative stool or rectal swab cultures is frequently used to
define loss of colonization, but some investigators have used a
single negative result or ≥2 negative consecutive stool or rectal
swab cultures [12, 13]. Further complicating these definitions
is the fact that intermittent fecal ARO detection after negative
cultures has been described in multiple studies [13–15]. The
potential limitations in sensitivity of detection of colonization
was further underscored in 1 study with findings suggesting
that vancomycin-resistant Enterococcus (VRE) colonization was
detectable and genotypically similar, as shown by pulse-field gel
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The Role of Fecal Microbiota Transplantation in Reducing
Intestinal Colonization With Antibiotic-Resistant
Organisms: The Current Landscape and Future Directions

Normal microbiome
resistant to colonization

Data on the frequency of patient outcomes after ARO colonization are mixed but important to quantify. The development of
United States Food and Drug Administration (FDA)–approved
treatments for decolonization may rely on improving outcomes
such as ARO infection. VRE colonization precedes infection
in immunocompromised patients [23]. Isendahl et al [24] reported population-level frequency estimates of bloodstream infection among patients with urine or fecal extended-spectrum
β-lactamase (ESBL)–producing Enterobacteriaceae colonization. Of patients with ESBL bloodstream infections, 98.6%
had antecedent urine or stool colonization [24]. More work is
needed to better determine which patients who are colonized
with AROs will become infected and to estimate the number of
colonized patients needed to treat to prevent infection, hospitalization, mortality, and other patient-centered outcomes.
THE HUMAN INTESTINAL MICROBIOME
AS A THERAPEUTIC TARGET FOR ARO
DECOLONIZATION

Although it is well established that anaerobic bacteria residing
in the intestine can limit ARO colonization, the ideal strategy to
modify intestinal microbiomes has not been defined. For decades,
the association of antibiotic administration and subsequent ARO
detection has been understood in part to be an indirect effect

Disrupted microbiome
susceptible to colonization

Colonization and
dominance by ARO

Infection and
potential for
transmission

ARO

Antibiotics

Fecal microbiota transplantation

Microbiome diversity restored
Figure 1. Concept illustration of intestinal microbial diversity as a protective factor against colonization with antibiotic-resistant organisms (AROs), adapted from Halpin
et al [25]. Antibiotic exposure can lead to disruption of these community structures and subsequent colonization and dominance by AROs, which may increase risk of infection and transmission to other patients. Fecal microbiota transplantation may reduce risk of ARO colonization and transmission by increasing intestinal microbiome diversity.
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electrophoresis, even in “cleared” patients 5 years after initial
detection [16].
Most published active surveillance studies of intestinal
ARO colonization demonstrate themes of prolonged colonization, intermittent periods of shedding, variability in isolate
recovery patterns by culture method and by ARO type, and
codetection of multiple AROs [14, 17–21]. The duration of
colonization also varies by ARO type. The reported median
duration of colonization was 306 days (range, 1–1393 days)
for VRE in 1 study [14] and 144 days (41–359 days) for
multidrug-resistant gram-negative bacteria in another
study [17], and the medians for carbapenem-resistant
Enterobacteriaceae (CRE) in 2 studies were 165 and 295 days
[19, 20]. Compared with patients with a single admission,
those readmitted to hospitals or post–acute care facilities
have been observed to have variable durations of colonization [20]. The majority of published studies documenting
the duration of ARO colonization have investigated outbreak scenarios or patients in acute care or post–acute care
facilities, where apparently persistent ARO colonization may
be due to ongoing ARO exposures and recolonization [22].
The variability in the natural history of ARO colonization
makes decolonization outcomes after FMT challenging to
interpret.

EFFICACY OF INTESTINAL MICROBIOME THERAPIES
FOR ARO DECOLONIZATION AMONG PATIENTS
WITH RCDI

The use of FMT for RCDI expanded after publication of a Dutch
randomized, controlled trial and the decision of the FDA to
allow the use of FMT under an enforcement discretion policy in
the United States. Some patients treated for RCDI were found
to also be colonized with other AROs, and in some these AROs
cleared after FMT (Table 1).

Stripling et al [41] described the decreased intestinal relative abundance of VRE in a heart-kidney transplant recipient
with RCDI and recurrent VRE infections treated with FMT. The
potential confounding of stopping vancomycin used for RCDI
treatment before FMT and decreased VRE relative abundance
in stool was acknowledged as a limitation [41]. However, an
increase in the relative abundance of genera that were differentially abundant in donor stool, such as Blautia, Akkermansia,
Rosburia, and Faecalibacterium, suggested a donor-derived benefit [41]. In a secondary analysis of a phase II study of a human
microbiota–derived product for treatment of RCDI, Dubberke
et al [12] noted that 8 of 11 patients (73%) who were VRE positive at baseline were negative for VRE at the last follow-up stool
culture. Using culture-independent techniques, Millan et al [45]
demonstrated a significant reduction in the count of antibiotic
resistance genes in the stool samples of patients with RCDI
with each successive FMT treatment. Notably, not all published
cases of RCDI and ARO colonization treated with FMT have
demonstrated successful ARO decolonization. Jang et al [39]
described a patient with RCDI and VRE stool colonization who
was persistently colonized with VRE after 2 FMTs.
EFFICACY OF FMT FOR ARO DECOLONIZATION AS
PRIMARY OUTCOME

Case reports, case series, and prospective studies have also
demonstrated the efficacy of FMT for ARO decolonization as
a primary outcome (Table 2). These studies were informed by
hypotheses of shared risk factors with RCDI and ARO colonization, mouse models, and secondary analyses of patients with
RCDI treated with FMT and found to have ARO decolonization.
Multiple case reports have described loss of ARO colonization after treatment with FMT. Freedman and Eppes [46]
described their clinical group’s eradication of carbapenemresistant Klebsiella pneumoniae colonization in a 14-year-old
girl with hemophagocytic lymphohistocytosis and 5 weeks of
persistently positive blood cultures with K. pneumoniae. Three
follow-up stool cultures over an 8-month period were negative
for K. pneumoniae and she had no recurrent infections over an
18-month follow-up period [46]. Lagier et al [48] described the
successful decolonization of a patient with intestinal colonization with OXA-48 carbapenemase producing K. pneumoniae.
In both patients, treatment with FMT was motivated by major
challenges presented by the ARO colonization. Although these
were single case patients without controls, these findings support further testing of hypotheses that ARO decolonization
with FMT could reduce ARO infection and improve care for
patients with limited options [46, 48].
Bilinski et al [49] reported the results of a prospective
study of FMT for ARO colonization in 20 patients with leukemia, multiple myeloma, and thrombotic thrombocytopenic
purpura. Efficacy assessments were based on follow-up at 1
week, 1 month, and 6 months after FMT. That study included
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mediated by off-target loss of anaerobic taxa as a consequence of
antianaerobic antimicrobial activity [17, 18, 24, 26]. This principle
was demonstrated by Donskey et al [18] in their prospective surveillance of density of VRE in stool of colonized patients, which
showed an expansion of VRE density in stool cultures of patients
receiving antianaerobic antibiotic regimens, compared with those
not receiving such regimens. Counterintuitively, gram-negative antibiotic treatment has been associated with a doubled risk of bacteremia in ESBL-colonized patients [24]. Similarly, O’Fallon et al [17]
noted that two-thirds of patients with persistent multidrug-resistant
gram-negative bacterial colonization did not receive antibiotics
during their prospective surveillance study, underscoring that
factors other than antibiotics also drive colonization.
These observations point to complex interactions between
healthy microbiota, AROs, and the host, which have been
reviewed elsewhere [27]. Key examples of mechanisms of colonization resistance include resistance to VRE colonization with
defined bacterial consortia and with viral and viruslike Toll-like
receptor simulation of the antimicrobial peptide Reg3γ [28,
29]. Another established mechanism of colonization resistance
is competition between commensals and potential pathogens
for dietary and host-derived glycans and metabolites that are
nutritional requirements [27]. As mechanisms of colonization
resistance continue to be elaborated, FMT is being explored as
a method to transfer these identified and unidentified AROresistant factors to ARO-colonized patients.
FMT is the process of transplanting stool from a healthy
donor to a diseased recipient. Practices similar to FMT have
been traced to the Dong-jin dynasty of fourth-century China
and reported in contemporary medical literature for treatment
of pseudomembranous colitis in 1958 [30, 31]. Since a landmark randomized controlled trial of FMT for treatment of recurrent Clostridioides difficile infection (RCDI) was published
in 2013, a number of clinical trials have demonstrated cure rates
of approximately 90% when repeated FMTs are included [31–
35]. FMT has become an important treatment for RCDI and is
included in major society guidelines including those produced
by the Infectious Disease Society of America and a number of
European professional societies [37, 38]. With increasing use of
FMT for RCDI, loss of ARO colonization has been increasingly
recognized as a collateral benefit in these patients and has been
described in increasing numbers of case reports and case series.

RCDI, VRE colonization
(n = 1)

RCDI, CR Pseudomonas,
MDR Acinetobacter, CR
Klebsiella, VRE, MRSA
(n = 1)

RCDI, recurrent VRE bacteremia, UTIs (n = 1)

RCDI, VIM-1–producing
K. oxytoca colonization
(n = 1)

RCDI, VRE colonization
(n = 11)

RCDI, RUTI (n = 8)

RCDI, RUTI (n = 1)

Jang et al [39]

Crum-Cianflone et al
[40]

Stripling et al [41]

García-Fernández
et al [42]

Dubberke et al [12]

Tariq et al [43]

Wang et al [44]

FMT Donor or Product, No.
of FMTs, Route

Son, 1, colonoscopy

Spouse, 1, nasogastric tube

Sister, 1, colonoscopy

Healthy donor, 1, colonoscopy

Clinical CDI cure; no UTI recurrence at 25
mo

Reduction in UTI frequency; overall
improved antibiotic susceptibility of
uropathogens

8/11 VRE culture negative at 1–6 mo

Clinical RCDI cure; VIM-1 Klebsiella oxytoca
culture and PCR negative at 6 wk and
6 mo

No further VRE infections or RCDI in year
after FMT

Clinical RCDI cure; reduced clinically indicated cultures obtained, 4/11 cultures
with AROs vs with 12/24 before FMT
No episodes of sepsis in post-FMT period

Clinical RCDI cure; VRE cultures did not
clear within time frame of follow-up

Outcomes

6

Diarrhea, flatulence,
abdominal pain and
cramping, constipation

None noted

25

12

6

Constipation at 6 wk

None noted

12

24

3

Duration of Follow-up,
mo

None noted

None noted

None noted

Adverse Events

Abbreviations: ARO, antibiotic-resistant organism; CDI, Clostridioides difficile infection; CR, carbapenem-resistant; FMT, fecal microbiota transplantation; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; PCR, polymerase chain
reaction; RCDI, recurrent CDI; RUTI, recurrent urinary tract infection; UTI, urinary tract infection; VIM-1, Verona integron–encoded metallo-β-lactamase 1; VRE, vancomycin-resistant Enterococcus spp.

Oral vancomycin

Variable treatment Healthy donor, doses not reported,
for CDI
colonoscopy

Variable treatment RBX2660, 1–2, rectal enema
for RCDI

Oral vancomycin

Oral vancomycin

Oral vancomycin

Oral vancomycin
Brother, 2, rectal enema
and intravenous
metronidazole

Infection/Colonization Status Pretreatment

Authors

Table 1. Summary of Published Case Reports and Series Describing Antibiotic-Resistant Organism Decolonization as Secondary Outcome Among Patients Treated With Fecal Microbiota Transplantation for
Recurrent Clostridioides difficile Infection
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n=1

Lagier et al [48]

“Full colon lavage” without
antibiotics

n = 10

Battipaglia et al
[51]

CPE or CPA

Saïdani et al [53] n = 10

Antibiotics, 2 bowel lavage (×2), PPI,
attempted nares decontamination
with chlorhexidine

Colistin/neomycin for 5 d

Bowel lavage, PPI administered
with NG FMTs, enema FMTs
requested 2–3-h retention,
antibiotics discontinued 48–72 h
earlier

Culture was negative at 1 mo in 3/15
Mild discomfort,
1 mo
patients with 1 FMT and 3/7 with 2 FMTs
temporary loose
stools

3 mo

• 3/8 CRE, 3/9 VRE culture negative at
None noted
1 mo
• 4/8 CRE, 7/8 VRE culture negative at 3 mo

1 mo

2 wk

3 mo

18 mo

Follow-up

3 mo

Vomiting, diarrhea

None noted

None noted

None noted

Adverse events

None noted

CRE culture negative at 1 and 3 mo in 2/6
patients; VRE culture negative in 1/2 at
3 mo (but not 1 mo)

Complete decolonization in 15/25
patients at 1 mo and in 13/14 at 6 mo

Culture negative for carbapenemaseproducing K. pneumoniae at 7 and 14 d;
PCR negative at 7 d

ESBL cultures of perineum and throat
negative at 1, 2, 4, and 12 wk; rectal
cultures negative at 2, 4, and 12 wk
though positive at 1 wk; patient able to
be relisted for renal transplantation

No clinical CP K. pneumoniae infection at
1.5 y; 3 stool cultures for CP K.
pneumoniae negative at 8 mo

Outcome

Negative for CPE/CPA at in 8/10 patients at
14 d; 8/15 “FMT success rate” (5 patients
had 2 FMTs)

Unrelated healthy
ITT: 9/22 patients (41%) in intervention
donors, capsules for 2 d at
group and 5/17 controls (29%)
some centers, NG tube for
decolonized;
1 dose at other centers
per protocol: 8/16 (50%) in intervention
group and 3/13 controls (23%)
decolonized

Mild, 4 severe adverse events
(1 classified as
possibly related
to FMTa)

6 mo

5–7 mo

Patient-known donors (n = 9) “Major decolonization” or 3 consecutive
Mild, diarrhea in 2 13-mo median
or unrelated donor (n = 1),
negative weekly cultures in 7/10 patients;
patients, constifollow-up
1 (n = 7) or 2 (n = 3),
persistent decolonization (negative at last
pation in 1
enema (n = 8) or NG tube
follow-up) in 6/10; ESBL decolonization
(n = 2)
noted as secondary outcome in 3/6

Healthy donor, 1–2,
nasoduodenal tube

Healthy donor, 1,
nasoduodenal tube

Universal donor, 1,
nasoduodenal tube

Healthy donor, 1–3 (25
FMTs in 20 subjects),
nasoduodenal tube

Donor not described, 1 50 g
of stool), infused by NG
tube

Young, healthy white adult,
nasoduodenal tube

Brother, 1, nasoduodenal
tube, probiotics for 6 mo

FMT Donor, No. of FMTs,
route

The severe adverse event classified as possibly related to FMT was hepatic encephalopathy in a cirrhotic patient.

a

Abbreviations: ARO, antibiotic-resistant organism; BSI, blood stream infection, CP, carbapenemase-producing; CPA, CP Acinetobacter; CPE, CP Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase–
producing Enterobacteriaceae; FMT, fecal microbiota transplantation; HLH, hemophagocytic lymphohistiocytosis; ITT, intention to treat; MDR, multidrug-resistant; NG, nasogastric, PPI, proton pump inhibitor, VRE, vancomycin-resistant Enterococcus.

ESBL, CRE

Huttner et al [52] n = 39

CRE, VRE, or MDR
Pseudomonas

Bowel lavage,
o antibiotics

n = 15

Singh et al [50]

ESBL colonization

PPI, bowel lavage, no antibiotics

Inpatients (n = 17)CRE or VRE colonization

Dinh et al [15]

Bowel lavage, PPI, with or without
antibiotics
Bowel lavage, PPI, no antibiotics

ARO colonization (ESBL,
OXA-48, CRE, VRE)

Davido et al [13] Inpatients (n = 8) CRE or VRE colonization

Bilinski et al [49] Blood disorders
(n = 20)

Renal transplant Recurrent ESBL transplant
recipient
pyelonephritis
(n = 1)

Singh et al [47]

Polyethylene glycol, omeprazole

Pretreatment

Asymptomatic stool
Bowel lavage, 4 administrations of
carriage of OXA-48
colistimethate sodium, gentaK. pneumoniae precluded
micin
placement in long-term
care

Recurrent otitis CP Klebsiella pneumoniae;
media, HLH,
BSI for 5 wk
osteomyelitis
(n = 1)

Freedman and
Eppes [46]

Indication

Patient (s)

Published Case Reports and Series Describing Outcomes of Fecal Microbiota Transplantation for Antibiotic-Resistant Organism Decolonization as Primary End Point

Authors

Table 2.
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of follow-up. A similar observation was reported in a casecontrol study of 8 patients with ≥3 RUTIs before FMT who
were matched to controls with 3 episodes of C. difficile infection
and ≥3 RUTIs not treated with FMT [43]. Patients with RUTIs
treated with FMT were shown to have a decrease in urinary
tract infections, from a median of 4 in the year before FMT to 1
in the year after FMT. E. coli antimicrobial susceptibilities were
noted to improve in the post-FMT setting for cephalosporins,
fluoroquinolones, and trimethoprim-sulfamethoxazole [43].
Taken together, these findings show potential efficacy of FMT
for decolonization of intestinal colonization with AROs. They
have also suggested potential differences in decolonization frequency by ARO type that could be related to pathogen-specific
colonization factors. These studies do have important limitations that should be addressed in future studies.

Effect of FMT for ARO Decolonization on Need for Contact Isolation

Limited Data for Long-Term Safety

One study comparing 10 patients undergoing FMT to treat
ARO colonization and 20 matched retrospective controls
demonstrated a decrease of 21.5 days in the median delay to
discharge [53]. These authors also reported a median decrease
in time to decolonization, from 50.5 to 3 days [53]. Although
discharge delays in this study were related to limitations in
facilities that were able to receive ARO-colonized patients, these
findings suggest that ARO decolonization with FMT could
present major cost savings to healthcare systems. They also underscore the potential public health impact of reducing transmission of AROs between patients.
Effect of FMT on Frequency of Recurrent Infections Other Than RCDI

Studies have also described a potential benefit of breaking the
cycle of recurrent urinary tract infections (RUTIs) after FMT
for RCDI. Wang et al [44] described an 83-year-old woman
with a 25-year history of RUTIs who was treated with FMT for
RCDI and had a complete cessation of RUTIs during 25 months
6 • ofid • Woodworth et al

LIMITATIONS OF PUBLISHED STUDIES ON FMT FOR
ARO DECOLONIZATION

Approaches for FMT for ARO decolonization are still early
in development. Accordingly, there are still important limitations in our understanding of the safety and efficacy of using
FMT for this indication. Most published studies lacked control
groups and long-term follow-up periods. They used varying
definitions of decolonization and nonstandardized treatment
protocols. These limitations restrict the generalizability of the
findings. Central questions remain about whether findings of
decolonization and decreased frequency of recurrent infections
after FMT are directly related to FMT treatments, to other selective pressures such as cessation of antibiotics, or to spontaneous decolonization events. The use of FMT outside healthcare
settings, as in travelers returning from locales with higher prevalence of AROs, may also warrant further study.

A number of FMT case reports and series have described new
diagnoses that were temporally associated with the administration of FMT. The intestinal microbiome has also been linked
to colorectal cancer, atherosclerosis, and thrombosis [54, 55].
These reports have raised a number of concerns about the
possible long-term metabolic, inflammatory and neoplastic
risks related to FMT. Long-term prospective cohort studies are
needed to further evaluate these potential risks.
Need for Mechanistic Studies and Control Groups in Clinical Trials of FMT
for ARO Decolonization

Preclinical studies have identified mechanisms of microbiomemediated ARO colonization resistance. For example, in the
case of C. difficile, bile-salt metabolism, gastrointestinal (GI)
luminal pH, and competition for resources are known to be
contributing factors in the development of infection [27].
Categories of AROs may occupy distinct spatial niches within
the GI tract [56]. Although clinical trials evaluating the efficacy
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no control group, and providers were permitted to prescribe
antibiotics, as indicated by clinical circumstances. The decolonization end point was met in 15 of 25 FMTs (60%) at
1 month and in 13 of 14 (93%) at 6 months, and Escherichia coli
was decolonized with more efficacy than K. pneumoniae [49].
A subset analysis showed that patients treated with FMT and
not prescribed antibiotics were more likely to reach the primary
end point of no ARO colonization at 1 month than patients who
were prescribed antibiotics [49].
Davido et al [13] reported outcomes of a French multicenter
pilot clinical study of FMT for decolonization with CRE and/
or VRE. At 1 and 3 months, 2 of 8 patients (25%) and 3 of 8
(38%), respectively, were decolonized [13]. The authors did
not identify characteristics that distinguished patients who
were decolonized at 1 month from those who were persistently
colonized, and no patients who were VRE colonized at baseline were decolonized at 1 month [13]. In a subsequent report
from the same multicenter group in France, Dinh et al [15]
described similar decolonization proportions of 3 of 8 (38%)
and 3 of 9 (33%) among CRE- and VRE-colonized patients, respectively, at 1 week after FMT. At 3 months, 4 or 8 (50%) and 7
of 8 (88%) CRE- and VRE-colonized patients, respectively, were
decolonized. In these French studies, no adverse events were reported, and there was no control group to compare the duration
of ARO colonization.
Singh et al [50] completed a study of FMT for decolonization of ESBL in 15 patients; when including patients who underwent a second FMT for persistently ESBL-positive cultures,
they found an overall decolonization rate of 40%. In their assessment, those authors suggested that differential efficacy between 2 stool donors may have accounted for the differences in
outcomes [50].

of FMT for treatment of RCDI have had control groups, to date
only 1 published prospective clinical trial of FMT for ARO decolonization has included a control group [52]. The lack of a
control group greatly weakens estimates of causal associations
between FMT and ARO decolonization.

Many case reports and case series to date have described
positive outcomes after FMT. However, the implicit risk of
publication bias against negative results of FMT for ARO decolonization should be acknowledged. In 1 of the few studies
published with mixed outcomes for FMT ARO decolonization,
Stalenhoef et al reported the detailed clinical history, microbiologic, and microbiome analyses for a patient treated with FMT
for Verona integron–encoded metallo-β-lactamase–producing
Pseudomonas aeruginosa. This Pseudomonas isolate was not
detected in the post-FMT setting, but an ESBL-producing
E. coli was, which they describe as a clinical success combined
with microbiologic failure [57]. They note that their patient
had “intact” microbiota diversity before FMT and question the
potential efficacy of FMT in patients with normal microbiota
diversity.
This potential issue was also observed in 2 negative studies of
FMT that were conducted to estimate its efficacy in treating
metabolic syndrome and chronic inflammation in virally
suppressed patients with human immunodeficiency virus infection [58, 59]. Diversity analyses describe the composition of
a microbial community at a high level but do not clarify the

Table 3.

PRACTICAL QUESTIONS AND PRIORITIES TO
IMPROVE FUTURE FMT CLINICAL STUDIES

In Table 3, we present a list of challenges, opportunities, and research priorities to improve the current understanding of FMT
for ARO decolonization. Although most studies published to
date included FMT pretreatments with bowel lavage, with or
without antibiotics (Tables 1 and 2), it is not clear whether this
step improves efficacy. In a pragmatic study of a lyophilized,
encapsulated FMT product taken orally, bowel lavage was abandoned after 4 patients, and the dose was decreased during the
study period without a clear compromise in efficacy [61]. These
and other practices, such as promotility medications and protonpump inhibitors coadministered with FMT when delivered via
an upper GI tract route or antidiarrheals when administered
via an enema, have not been validated in controlled studies.
Evidence supporting these practices is generally at the level of

Proposed Practical Research Agenda for Future Study of Fecal Microbiota Transplantation for Antibiotic-Resistant Organism Decolonization

Existing Challenge

Recommendations

Wide variability in FMT approaches in published literature

Multicenter clinical trial consortia should be funded to reduce variability in research
approaches, improve rigor and reproducibility, and streamline protocol development to
study the following prospectively:
Ideal feces donor characteristics for ARO decolonization
FMT dosing frequency and thresholds for repeating treatment
Risks/benefits of bowel-preparation, antibiotic pretreatment
Differential effects on specific AROs
FMT recipient host factors that modulate FMT efficacy
Improve recruiting capacity for rare cases (extreme multidrug resistance)
ARO detection in feces in control groups in setting of ongoing antibiotic pressure and varied
place of residence
Benefits to patients of tailored microbiome therapies of microbial consortia or rationally
matched donors

Regulatory future of FMT remains unclear

FDA, industry, and academics should work collaboratively to maintain patient-centered regulatory approaches that balance needs for further study with access to therapies with an
immediate need

Unrefined end points of clinical studies

Benchmarking studies are needed to compare the performance characteristics of culturebased, culture-independent, and mixed methods that incorporate both approaches;
measures of ARO decolonization should be studied to better estimate precision by
number of consecutive swab samples, combining swab samples with PCR- or NGS-based
techniques

Limited long-term safety outcomes data

Long-term cohorts and registries are needed to study the long-term safety of microbiome
therapeutics

Abbreviations: ARO, antibiotic-resistant organism; FDA, Food and Drug Administration; FMT, fecal microbiota transplantation; NGS, next-generation sequencing; PCR, polymerase chain
reaction.
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Need for Further Study of Clinical Failures to Improve Mechanistic
Understanding

functional capacity of these communities. It is also likely that
FMT may not be effective for nonintestinal or non–genitourinary tract reservoirs of colonization by ARO (eg, biliary or pulmonary). New analytic tools and databases are being developed
that allow analyses of the gene-predicted functional capacity
of microbial communities with metagenomic whole-genome
sequencing [60]. These tools support moving beyond diversity measures alone and improved understanding of how taxa
and their functional capacity may reduce ARO colonization. In
turn, this could inform selection of minimal or ideal taxa to include in rationally developed microbiome therapeutics.

the potential to reduce ARO colonization by restoring microbial community composition and function, but further study
is necessary. We have outlined a practical research agenda that
we believe will improve our current understanding of the safety
and efficacy of FMT for ARO colonization and may improve
patient care.
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Regulatory, Ethical, and Practical Considerations

Important questions remain for providers and patients about
the use of FMT for ARO decolonization. The regulatory status
of FMT remains in flux, but currently the US FDA requires
an approved investigational new drug application for all uses
of FMT other than RCDI. For RCDI, the FDA has chosen to
exercise enforcement discretion. This means that an investigational new drug application is not required but patients should
provide consent informed by the discussion of potential risks
and the investigational nature of FMT. The novelty of FMT has
brought a host of new questions, including whether the material used in FMT is of human origin, akin to a tissue, or if it
is a drug that must be consistently manufactured with good
manufacturing principles. In addition, naturally occurring
substances cannot be patented, which has motivated isolation
of variants or derivatives of stool or the active components of
FMT to balance drug development costs. On the other hand,
patient and FMT-provider advocacy groups have asserted that
FMT should remain available in its current form, with access to
public stool banks and without explicit FDA approval.
We encourage providers to continue to advocate for patients
to ensure access to potentially effective therapies. In the meantime, FMT should not become the standard of care before the
safety and efficacy of FMT is rigorously tested in prospective
blinded, randomized, controlled trials. Partnership with the
FDA for investigational new drug applications, institutional review boards, academics, ethicists, and industry will be necessary for further development of these therapies.

CONCLUSIONS

The intestinal microbiome is a potentially promising target
to directly reduce ARO colonization and possibly subsequent
ARO infection. Early evidence suggests that FMT may have
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